Executive Director, Key Accounts Lead at Summit Therapeutics in Field

Job description

About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. Overview of Role: As a key member of the Market Access leadership team, the Executive Director, Key Accounts leader will help lead the preparation, development, and execution of market access account strategies.. This is a critical customer facing role to helping to ensure broad access, reimbursement, and patient affordability. The individual will be responsible for building and maintaining relationships with key oncology stakeholders, including Specialty GPOs/Aggregators, Oncology Supergroups, Key Community Oncology practices, IDNs, Guideline and Pathway organizations. Additionally, the Executive Director, Key Accounts will lead the Key Accounts field account team and collaborate closely with Payer Strategic Accounts and sales teams, as well as internal teams, to integrate customer and market insights into pricing, contracting, and market access strategies and plans. Role and Responsibilities: Team Leadership: Build, train, and lead the account management field team (GPOs, Community Oncology, IDNs, and other Access Stakeholders) to develop and execute strategic business plans that align with overall objectives, maximize product access, and ensure reimbursement. Stakeholder Engagement: Establish and maintain relationships with key decision-makers, including Formulary, P&T, and Pathway leaders, Medical & Pharmacy Directors and other population-based stakeholders to secure appropriate access and optimal product positioning. Leadership and Influence: Demonstrate leadership among various customer groups and Access stakeholders, including GPOs, Community Oncology practices, IDNs, Pathway Committee members, and others ( State Societies , COA, NCODA, etc.). Cross-functional Collaboration: Partner with internal teams (Market Access, Medical Affairs, HEOR, Commercial Operations, Regulatory, Legal, Finance, Marketing, Sales, etc.) to address reimbursement challenges and develop coordinated solutions that are compliant and effective. Strategy Development: Co-create strategies, tools, and tactics for the field team to comm